SAN FRANCISCO, Oct. 29, 2015 /PRNewswire/ -- Nektar
Therapeutics (Nasdaq: NKTR) will announce its financial results for
the third quarter ended September 30,
2015 on Thursday, November 5,
2015, after the close of U.S.-based financial markets.
Howard Robin, president and chief
executive officer, will host a conference call to review the
results beginning at 5:00 p.m. Eastern
Time (ET)/2:00 p.m. Pacific
Time (PT).
The press release and a live audio-only Webcast of the
conference call can be accessed through a link that is posted on
the home page and Investor Relations section of the Nektar website:
http://www.nektar.com. The web broadcast of the conference call
will be available for replay through Monday,
December 7, 2015.
To access the conference call, follow these instructions:
Dial: (877) 881-2183 (U.S.); (970) 315-0453 (international)
Passcode: 65851649 (Nektar Therapeutics is the host)
In the event that any non-GAAP financial measure is discussed on
the conference call that is not described in the press release, or
explained on the conference call, related information will be made
available on the Investor Relations page at the Nektar website as
soon as practical after the conclusion of the conference call.
About Nektar
Nektar Therapeutics has a robust R&D
pipeline in pain, oncology, hemophilia and other therapeutic areas.
In the area of pain, Nektar has an exclusive worldwide license
agreement with AstraZeneca for MOVANTIK™ (naloxegol), the first
FDA-approved once-daily oral peripherally-acting mu-opioid receptor
antagonist (PAMORA) medication for the treatment of opioid-induced
constipation (OIC), in adult patients with chronic, non-cancer
pain. The product is also approved in the European Union as
MOVENTIG® (naloxegol) and is indicated for adult patients with OIC
who have had an inadequate response to laxatives. The AstraZeneca
agreement also includes NKTR-119, an earlier stage development
program that is a co-formulation of MOVANTIK and an opioid.
NKTR-181, a wholly-owned mu-opioid analgesic molecule for chronic
pain conditions, is in Phase 3 development. NKTR-171, a
wholly-owned new sodium channel blocker being developed as an oral
therapy for the treatment of peripheral neuropathic pain, is in
Phase 1 clinical development. In hemophilia, ADYNOVATE™
[Antihemophilic Factor (Recombinant)], a longer-acting PEGylated
Factor VIII therapeutic has been filed for approval in the U.S. by
partner Baxalta Inc. In anti-infectives, Amikacin Inhale is in
Phase 3 studies conducted by Bayer Healthcare as an adjunctive
treatment for intubated and mechanically ventilated patients with
Gram-negative pneumonia.
Nektar's technology has enabled nine approved products in the
U.S. or Europe through
partnerships with leading biopharmaceutical companies, including
AstraZeneca's MOVANTIK™, UCB's Cimzia® for Crohn's disease and
rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's
Neulasta® for neutropenia.
Nektar is headquartered in San
Francisco, California, with additional operations in
Huntsville, Alabama and
Hyderabad, India. Further
information about the company and its drug development programs and
capabilities may be found online at http://www.nektar.com.
MOVANTIK™ is a trademark and MOVENTIG® is a registered trademark
of the AstraZeneca group of companies.
ADYNOVATE is a trademark of Baxalta Inc.
CONTACT: Jennifer Ruddock of
Nektar Therapeutics, +1-415-482-5585
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nektar-to-announce-financial-results-for-the-third-quarter-2015-on-thursday-november-5-2015-after-close-of-us-based-financial-markets-300169192.html
SOURCE Nektar Therapeutics